p53, guardian of the genome
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53, famously known as the ‘Guardian of the genome’ plays a key role in manifestation of cellular senescence via several different mechanisms (Lane, 1992; Kastenhuber and Lowe, 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Lane, 1992
In the citing paper
“p53 is an crucial tumor suppressor that is mutated in more than 50% of human cancers”
From USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 (2010) · cites this paper as Lane, 1992
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Research works printed but not linked: 3
- Sturzbecher, H.-W. Oncogene (in the press).
- Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Cancer Res. 51, 6304–6311 (1991).
- Bischoff, F. Z. et al. Cancer Res. 50, 7979–7984 (1990).
Cited by
Items 501–600 of 1,031
BAYEVER, E., IVERSEN, P. L., BISHOP, M. R., SHARP, J. G., TEWARY, H. K., ARNESON, M. A., PIRRUCCELLO, S. J., RUDDON, R. W., KESSINGER, A., ZON, G., et al. (1993) · Antisense Research and Development · doi:10.1089/ard.1993.3.383 · Cited by 149
“The mutant form ofthe phosphoprotein p53 has been associated with a wide variety of human cancers (Levine et al., 1991; Lane, 1992).”
Two metachronous tumors in the radiotherapy fields of a patient with Li‐Fraumeni syndrome
Limacher, J., Frebourg, T., Natarajan‐Ame, S., & Bergerat, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1021 · Cited by 149
“This hypothesis is strengthened by the following experimental data: (i) p53 is involved in the control of genomic integrity, particularly after a genotoxic aggression [18].”
MethodFankhauser, C., Marks, J., Reymond, A., & Simanis, V. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05931.x · Cited by 149
The dual role model for p53 in maintaining genomic integrity
Janus, F., Albrechtsen, N. J. W., Dornreiter, I., Wiesmüller, L., Große, F., & Deppert, W. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050266 · Cited by 351
Toh, Y., Oki, E., Ohgaki, K., Sakamoto, Y., Ito, S., Egashira, A., Saeki, H., Kakeji, Y., Morita, M., Sakaguchi, Y., et al. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-010-0057-6 · Cited by 167
Lulla, R. R., Goldman, S., Yamada, T., Beattie, C. W., Bressler, L., Pacini, M., Pollack, I. F., Fisher, P. G., Packer, R. J., Dunkel, I. J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now047 · Cited by 148
ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies
Rinaldi, M., Caffo, M., Minutoli, L., Marini, H. R., Abbritti, R. V., Squadrito, F., Trichilo, V., Valenti, A., Barresi, V., Altavilla, D., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060984 · Cited by 167
Tumor Radiosensitivity and Apoptosis
Zhivotovsky, B., Joseph, B., & Orrenius, S. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4452 · Cited by 168
p53 gene mutations in pituitary adenomas: rare events
Levy, A., Hall, L., Yeudall, W. A., & Lightman, S. L. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02797.x · Cited by 150
Rasbridge, S., Gillett, C. E., Seymour, A.-M., Patel, K., Richards, M., Rubens, R., & Millis, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.303 · Cited by 148
Telomere loss in cells treated with cisplatin
Ishibashi, T., & Lippard, S. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4219 · Cited by 152
Koduru, P. R. K., Raju, K., Vadmal, V., Menezes, G., Shah, S., Susin, M., Kolitz, J. E., & Broome, J. D. (1997) · Blood · doi:10.1182/blood.v90.10.4078 · Cited by 148
Soong, R., Robbins, P., Dix, B. R., Grieu, F., Lim, B. H. G., Knowles, S., Williams, K. E., Turbett, G. R., House, A. K., & Iacopetta, B. J. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90282-8 · Cited by 147
PATHOGENESIS OF RHEUMATOID ARTHRITIS: THE ROLE OF SYNOVIOCYTES
Yamanishi, Y., & Firestein, G. S. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70206-4 · Cited by 158
p53 GENE MUTATIONS AND PHOTOCARCINOGENESIS
Nataraj, A. J., Trent, J. C., & Ananthaswamy, H. N. (1995) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1995.tb05262.x · Cited by 167
Lilyestrom, W., Klein, M. G., Zhang, R., Joachimiak, A., & Chen, X. S. (2006) · Genes & Development · doi:10.1101/gad.1456306 · Cited by 132
“…1999; Kim et al. 2001). p53 was first identified as a cellular protein interacting with LTag (Lane and Crawford 1979; Crawford et al. 1980), and subsequently its critical role in regulating cell growth and maintaining genomic stability was estab- lished (Lane 1992; Levine 1997; Zhao et al. 2000).”
BackgroundMicroRNAs: Milk's epigenetic regulators
Melnik, B. C., & Schmitz, G. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.10.003 · Cited by 160
McKenzie, R. C., Arthur, J. R., & Beckett, G. J. (2002) · Antioxidants & Redox Signaling · doi:10.1089/152308602753666398 · Cited by 146
Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions
Li, C., Pazgier, M., Li, C., Yuan, W., Liu, M., Wei, G., Lu, W.-Y., & Lu, W. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.005 · Cited by 145
Apoptosis and Programmed Cell Death in Health and Disease
Vermes, I., & Haanen, C. (1994) · Advances in clinical chemistry · doi:10.1016/s0065-2423(08)60336-4 · Cited by 168
Pontén, F., Berne, B., Ren, Z.-P., Nistér, M., & Pontén, J. (1995) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12321071 · Cited by 156
Anti-proliferative activity and mechanism of action of titanocene dichloride
Christodoulou, C., Eliopoulos, A. G., Young, L. S., Hodgkins, L., Ferry, D. R., & Kerr, D. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.352 · Cited by 145
Role of p53 in Neurodegenerative Diseases
Chang, J. R., Ghafouri, M., Mukerjee, R., Bagashev, A., Chabrashvili, T., & Sawaya, B. E. (2012) · Neurodegenerative Diseases · doi:10.1159/000329999 · Cited by 134
Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer
Naccarati, A., Polakova, V., Pardini, B., Vodickova, L., Hemminki, K., Kumar, R., & Vodicka, P. (2012) · Mutagenesis · doi:10.1093/mutage/ger067 · Cited by 143
Recent Advances in the Biology of Heavy-Ion Cancer Therapy
Hamada, N., Imaoka, T., Masunaga, S., Ogata, T., Okayasu, R., Takahashi, A., Kato, T. A., Kobayashi, Y., Ohnishi, T., Ono, K., et al. (2010) · Journal of Radiation Research · doi:10.1269/jrr.09137 · Cited by 154
Nishizaki, T., DeVries, S., Chew, K., Goodson, W. H., Ljung, B., Thor, A. D., & Waldman, F. M. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199708)19:4<250::aid-gcc7>3.0.co;2-w · Cited by 184
Inflammation, carcinogenesis and cancer
Fitzpatrick, F. A. (2001) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00102-3 · Cited by 165
Fisher, C., Gillett, C. E., Vojtěšek, B., Barnes, D. M., & Millis, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.4 · Cited by 145
Siede, W., Friedberg, A. S., Dianova, I., & Friedberg, E. C. (1994) · Genetics · doi:10.1093/genetics/138.2.271 · Cited by 147
Kunz, C., Pebler, S., Otte, J., & von der Ahe, D. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.18.3710 · Cited by 144
The Role of p53 in Cell Cycle Regulation
Shaw, P. H. (1996) · Pathology - Research and Practice · doi:10.1016/s0344-0338(96)80088-4 · Cited by 169
The regulation of p53 function: Steiner award lecture
Lane, D. P. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570502 · Cited by 144
Self-citationDirect involvement of p53 in the base excision repair pathway of the DNA repair machinery
Offer, H., Wolkowicz, R., Matas, D., Blumenstein, S., Livneh, Z., & Rotter, V. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00505-0 · Cited by 144
p53 as guardian of the mitochondrial genome
Park, J., Zhuang, J., Li, J., & Hwang, P. M. (2016) · FEBS Letters · doi:10.1002/1873-3468.12061 · Cited by 143
Dubey, P., Hendrickson, R. C., Meredith, S. C., Siegel, C. T., Shabanowitz, J., Skipper, J. C. A., Engelhard, V. H., Hunt, D. F., & Schreiber, H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.695 · Cited by 146
“tion when DNA is damaged (52), and it is possible that p68 may serve a similar function as a tumor suppressor gene.”
BackgroundThe cell death machinery governed by the p53 tumor suppressor in response to DNA damage
Yoshida, K., & Miki, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01488.x · Cited by 175
Revisiting TP 53 Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas
Takami, H., Yoshida, A., Fukushima, S., Arita, H., Matsushita, Y., Nakamura, T., Ohno, M., Miyakita, Y., Shibui, S., Narita, Y., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12173 · Cited by 151
Regulation of Joint Destruction and Inflammation by p53 in Collagen-Induced Arthritis
Yamanishi, Y., Boyle, D. L., Pinkoski, M. J., Mahboubi, A., Lin, T., Han, Z., Zvaifler, N. J., Green, D. R., & Firestein, G. S. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64356-8 · Cited by 142
“The tumor suppressor gene p53 has well-established roles in cell-cycle control and apoptosis in response to DNA damage.(8) Such damage is found in rheumatoid synovium,(9) perhaps as a consequence of reactive oxygen and nitric oxide produced during inflammation.”
BackgroundThe role of cell cycle regulatory proteins in the pathogenesis of melanoma
Li, W., Sanki, A., Karim, R. Z., Thompson, J. F., Lee, C. S., Zhuang, L., McCarthy, S. W., & Scolyer, R. A. (2006) · Pathology · doi:10.1080/00313020600817951 · Cited by 158
Elsaleh, H., Powell, B. L., Soontrapornchai, P., Joseph, D. J., Goria, F., Spry, N. A., & Iacopetta, B. J. (2000) · Oncology · doi:10.1159/000012079 · Cited by 142
Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells
Cordani, M., Butera, G., Pacchiana, R., Masetto, F., Mullappilly, N., Riganti, C., & Donadelli, M. (2020) · Biomolecules · doi:10.3390/biom10030361 · Cited by 150
“Since p53 prevents cell mutations by promoting the DNA damage repair in injured cells, it is also called “guardian of genome” [61,62].”
BackgroundDiscovering novel chemotherapeutic drugs for the third millennium
Garrett, M. D., & Workman, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00280-4 · Cited by 151
Baskar, R., Li, L., & Moore, P. K. (2006) · The FASEB Journal · doi:10.1096/fj.06-6255com · Cited by 145
“induce p53, a guardian of the genome (29), and”
BackgroundTP53 in hematological cancer: Low incidence of mutations with significant clinical relevance
Peller, S., & Rotter, V. (2003) · Human Mutation · doi:10.1002/humu.10190 · Cited by 142
“Mutant p53, on the other hand, cannot arrest cells at G1 and can deregulate apoptosis resulting in malignant transformation and proliferation [Lane, 1992; Levine, 1997; El-Deiry et al., 1994; Sigal and Rotter, 2000].”
BackgroundTemporal Events in Skin Injury and the Early Adaptive Responses in Ultraviolet-Irradiated Mouse Skin
Ouhtit, A., Muller, H., Davis, D. W., Ullrich, S. E., McConkey, D. J., & Ananthaswamy, H. N. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64720-7 · Cited by 162
Antibodies against p53 are associated with poor prognosis of colorectal cancer
Houbiers, J. G. A., van der Burg, S., van de Watering, L., Tollenaar, R., Brand, A., van de Velde, C., & Melief, C. J. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.386 · Cited by 141
p53 Isoforms and Their Implications in Cancer
Vieler, M., & Sanyal, S. (2018) · Cancers · doi:10.3390/cancers10090288 · Cited by 140
“genomic stability [1] until maturity and even beyond [50].”
BackgroundPapp, T., Pemsel, H., Zimmermann, R., Bastrop, R., Weiss, D. G., & Schiffmann, D. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.8.610 · Cited by 139
p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis
Su, X., Chakravarti, D., & Flores, E. R. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3446 · Cited by 156
Mészáros, B., Kumar, M., Gibson, T. J., Uyar, B., & Dosztányi, Z. (2017) · Science Signaling · doi:10.1126/scisignal.aak9982 · Cited by 141
Anwar, J., Wrone, D. A., Kimyai‐Asadi, A., & Alam, M. (2004) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2003.12.006 · Cited by 139
Introduction: p53 – the first twenty years
Oren, M., & Rotter, V. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050265 · Cited by 180
The central region of HDM2 provides a second binding site for p53
Yu, G. W., Rudiger, S., Veprintsev, D., Freund, S., Fernandez-Fernandez, M. R., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510343103 · Cited by 138
Sabbatini, P., & McCormick, F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24263 · Cited by 140
Marrogi, A. J., Munshi, A., Merogi, A. J., Ohadike, Y., El-Habashi, A., Marrogi, O. L., & Freeman, S. M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971021)74:5<492::aid-ijc3>3.0.co;2-z · Cited by 183
p53 abnormalities in different subtypes of human sarcomas.
Andreassen, Å. K., Øyjord, T., Hovig, E. J., Holm, R., Flørenes, V. A., Nesland, J. M., Myklebost, O., Høie, J., Bruland, Ø. S., & Børresen‐Dale, A. (1993) · PubMed · Cited by 150
Johnson, P., Chung, S., & Benchimol, S. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.3.1456 · Cited by 140
The molecular epidemiology of P53 gene mutations in human breast cancer
Hartmann, A., Blaszyk, H., Kovach, J. S., & Sommer, S. S. (1997) · Trends in Genetics · doi:10.1016/s0168-9525(96)10043-3 · Cited by 139
Atlas of Genetics and Cytogenetics in Oncology and Haematology
(2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/15655 · Cited by 139
Update on Human Polyomaviruses and Cancer
Gjoerup, O. V., & Chang, Y. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)06001-x · Cited by 159
“The p53 protein has earned the nickname “Guardian of the Genome” (Lane, 1992), because it responds to many types of cellular stress 26 Ole Gjoerup and Yuan Chang (e.g., genotoxic or oncogenic stress) by imposing either cell-cycle arrest, apoptosis, or senescence mediated by transcriptional control…”
BackgroundPhase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.
Bishop, M. R., Iversen, P. L., Bayever, E., Sharp, J. G., Greiner, T. C., Copple, B. L., Ruddon, R., Zon, G., Spinolo, J., Arneson, M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1320 · Cited by 136
p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis
Ghosh, S., Salot, S., Sengupta, S., Navalkar, A., Ghosh, D., Jacob, R. S., Das, S., Kumar, R., Jha, N. N., Sahay, S., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.105 · Cited by 146
Tan, B. S., Tiong, K. H., Choo, H. L., Fei-Lei Chung, F., Hii, L.-W., Tan, S. H., Yap, I. K., Pani, S., Khor, N. T., Wong, S. F., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.191 · Cited by 136
Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs
Baell, J. B., & Huang, D. C. S. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01148-6 · Cited by 153
Redox Regulation of DNA Repair: Implications for Human Health and Cancer Therapeutic Development
Luo, M., He, H., Kelley, M. R., & Georgiadis, M. M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2698 · Cited by 134
Genetic Alterations in Esophageal Cancer
Kuwano, H., Kato, H., Miyazaki, T., Fukuchi, M., Masuda, N., Nakajima, M., Fukai, Y., Sohda, M., Kimura, H., & Faried, A. (2004) · Surgery Today · doi:10.1007/s00595-004-2885-3 · Cited by 140
A novel cytostatic process enhances the productivity of Chinese hamster ovary cells
Fussenegger, M., Mazur, X., & Bailey, J. E. (1997) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19970920)55:6<927::aid-bit10>3.0.co;2-4 · Cited by 136
Asymmetric triplex metallohelices with high and selective activity against cancer cells
Faulkner, A. D., Kaner, R. A., Abdallah, Q., Clarkson, G. J., Fox, D. J., Gurnani, P., Howson, S. E., Phillips, R. M., Roper, D. I., Simpson, D. H., et al. (2014) · Nature Chemistry · doi:10.1038/nchem.2024 · Cited by 144
Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer
Gavalas, N. G., Liontos, M., Trachana, S. P., Bagratuni, T., Arapinis, C., Liacos, C., Dimopoulos, M. A., & Bamias, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140815885 · Cited by 149
Laín, S., Midgley, C., Sparks, A., Lane, E. B., & Lane, D. P. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4433 · Cited by 149
Self-citationThe programmed death phenomena, aging, and the Samurai law of biology
Skulachev, V. P. (2001) · Experimental Gerontology · doi:10.1016/s0531-5565(01)00109-7 · Cited by 142
Roth, J., König, C., Wienzek, S., Weigel, S., Ristea, S., & Dobbelstein, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8510-8516.1998 · Cited by 135
“In this case, p73 may represent a differentiation factor in certain tissues rather than a general “guardian of the genome,” as suggested for p53 (17).”
Backgroundp53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma
Harpaz, N., Peck, A. L., Yin, J., Fiel, M. I., Hontanosas, M., Tong, T. R. S.-W., Laurin, J. N., Abraham, J. M., Greenwald, B. D., & Meltzer, S. J. (1994) · Human Pathology · doi:10.1016/0046-8177(94)90067-1 · Cited by 134
Toufektchan, E., & Toledo, F. (2018) · Cancers · doi:10.3390/cancers10050135 · Cited by 134
British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice
Morrison, J., Balega, J., Buckley, L., Clamp, A. R., Crosbie, E. J., Drew, Y., Durrant, L., Forrest, J., Fotopoulou, C., Gajjar, K. B., et al. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.11.423 · Cited by 155
MDM2-dependent ubiquitination of nuclear and cytoplasmic P53
Yu, Z. K., Geyer, R. K., & Maki, C. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203980 · Cited by 151
“The e ect of increasing p53 is to stop cell proliferation, either through a G1 cell cycle arrest or apoptotic cell death (Lane, 1992; Levine, 1997).”
BackgroundApoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent
Kinscherf, R., Claus, R., Wagner, M., Gehrke, C., Kamencic, H., Hou, D., Nauen, O., Schmiedt, W., Kovacs, G., Pill, J., et al. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.6.461 · Cited by 134
Transcription-Factor Mutations and Disease
Latchman, D. S. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340108 · Cited by 133
C ell C ycle D ysregulation in O ral C ancer
Todd, R., Hinds, P. W., Münger, K., Rustgi, A. K., OPITZ, O. G., Suliman, Y., & Wong, D. T. (2002) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130201300106 · Cited by 162
“Thus, p53 is involved in maintaining the integrity of the genome and has been referred to as the 'guardian of the human genome' (Lane, 1992).”
BackgroundNiewiadomska, G., Niewiadomski, W., Steczkowska, M., & Gasiorowska, A. (2021) · Life · doi:10.3390/life11010028 · Cited by 131
Liontas, A., & Yeger, H. (2004) · PubMed · Cited by 132
Soares, J., Pinto, A. E., Cunha, C. V., Andr�, S., Bar�o, I., Sousa, J. M., & Cravo, M. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990101)85:1<112::aid-cncr16>3.0.co;2-t · Cited by 187
Therapy Related Leukemias: Susceptibility, Prevention and Treatment
Leone, G. G. M., Voso, M. T., Sica, S., Roberta Morosetti, A., & Pagano, L. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109057981 · Cited by 132
Rubin, L. L., Philpott, K. L., & Brooks, S. F. (1993) · Current Biology · doi:10.1016/0960-9822(93)90211-6 · Cited by 132
Munsch, D., Watanabe-Fukunaga, R., Bourdon, J.-C., Nagata, S., May, E., Yonish-Rouach, E., & Reisdorf, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.3867 · Cited by 131
Dual Role of p53 in Innate Antiviral Immunity
Rivas, C., Aaronson, S. A., & Muñoz‐Fontela, C. (2010) · Viruses · doi:10.3390/v2010298 · Cited by 145
Loss of PUMA protects the ovarian reserve during DNA-damaging chemotherapy and preserves fertility
Nguyen, Q., Zerafa, N., Liew, S. H., Morgan, F. H., Strasser, A., Scott, C. L., Findlay, J. K., Hickey, M., & Hutt, K. J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0633-7 · Cited by 135
Human Papillomavirus E6 and E7: Proteins which deregulate the cell cycle
Tommasino, M., & Crawford, L. (1995) · BioEssays · doi:10.1002/bies.950170607 · Cited by 131
p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas.
Bolshakov, S. V., Walker, C. M., Strom, S. S., Selvan, M. S., Clayman, G. L., El‐Naggar, A. K., Lippman, S. M., Kripke, M. L., & Ananthaswamy, H. N. (2003) · PubMed · Cited by 130
The Retinoblastoma Gene: A Prototypic and Multifunctional Tumor Suppressor
Zheng, L., & Lee, W. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5129 · Cited by 157
Tu, Y., Chen, C., Pan, J., Xu, J., Zhou, Z., & Wang, C. (2012) · Europe PMC (PubMed Central) · Cited by 164
Harris, K. F., Christensen, J. B., & Imperiale, M. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.4.2378-2386.1996 · Cited by 130
Dudenhöffer, C., Rohaly, G., Will, K., Deppert, W., & Wiesmüller, L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5332 · Cited by 130
“This phenotype has been explained by the loss of p53 cell cycle checkpoint control (38, 39, 46).”
BackgroundSoini, Y., Chia, S.-C., Bennett, W. P., Groopman, J. D., Wang, J.-S., DeBenedetti, V. M. G., Cawley, H., Welsh, J.-A., Hansen, C., Bergasa, N. V., et al. (1996) · Carcinogenesis · doi:10.1093/carcin/17.5.1007 · Cited by 128
Nardone, G., Staibano, S., Rocco, A., Mezza, E., D’Armiento, F. P., Insabato, L., Coppola, A., Salvatore, G., Lucariello, A., Figura, N., et al. (1999) · Gut · doi:10.1136/gut.44.6.789 · Cited by 140
Reznikoff, C. A., Belair, C., Savelieva, E., Zhai, Y., Pfeifer, K., Yeager, T., Thompson, K. J., DeVries, S., Bindley, C., & Newton, M. A. (1994) · Genes & Development · doi:10.1101/gad.8.18.2227 · Cited by 129
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End
Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 123
“1). p53 is widely acknowledged as the guardian of the genome (Lane 1992).”
BackgroundBanks, D., Wu, M., Higa, L. A., Gavrilova, N., Quan, J., Ye, T., Kobayashi, R., Sun, H., & Zhang, H. (2006) · Cell Cycle · doi:10.4161/cc.5.15.3150 · Cited by 127
Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells
Maimets, T., Neganova, I. E., Armstrong, L., & Lako, M. (2008) · Oncogene · doi:10.1038/onc.2008.166 · Cited by 132
Weirauch, M. T., & Hughes, T. R. (2011) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-90-481-9069-0_3 · Cited by 151
Metadata
- Authors
- Lane, D. P.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Lane, D. P.
- ORCID
- Lane, D. P.
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 15-16
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2012053348
- Cited by
- 5,138
- References
- 19
- Citations by year
- 2026: 84 · 2025: 92 · 2024: 122 · 2023: 112 · 2022: 135 · 2021: 142 · 2020: 150 · 2019: 128 · 2018: 140 · 2017: 138 · 2016: 142 · 2015: 135 · 2014: 150 · 2013: 142 · 2012: 143
- FWCI
- 97.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TP53, p53, TP53 mutation, cancer, genome stability, tumor suppressor
- MeSH terms
- Animals, Chromosome Mapping, DNA Damage, DNA Repair, DNA-Binding Proteins, Gene Expression Regulation, Humans, Oncogenes, Transcription Factors, Genes, Tumor Suppressor, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.